What Kabiven Peripheral Treats: Main Uses and Benefits

This infusion is commonly used to counteract severe nutritional deficit and the resulting physiological strain when traditional eating or tube feeding is impossible or insufficient. It is used to provide a complete intravenous diet, supplying essential calories, protein (Amino Acids), and essential fats to support systemic functions and well-being during periods of acute illness or inability to absorb nutrients.

Kabiven Peripheral is used to manage the physiological state of negative nitrogen balance, a symptom related to heightened physiological stress. By providing a readily available source of Amino Acids, this therapy contributes to easing protein wasting and supports general well-being during symptomatic phases. Common therapeutic applications include managing severe malabsorption issues, providing perioperative support, and addressing the severe depletion of energy, protein, or essential fatty acids.

“This therapy contributes to easing protein wasting and supports general well-being during symptomatic phases.”

Kabiven Peripheral is indicated for use as a source of complete nutrition in adult patients when oral or enteral feeding is impossible, insufficient, or contraindicated. It may also be used in children aged two years and above in some regulatory regions.

Contraindicated Populations (Must Not Use)

Official labeling strictly prohibits use in patients with:

• Known Hypersensitivity: Allergy to egg, soybean, peanut proteins, corn, or any of the product’s components.
• Metabolic Disorders: Severe hyperlipidemia (serum triglycerides exceeding 1,000 mg/dL), inborn errors of amino acid metabolism, or hemophagocytic syndrome.
• Clinical Instability: Cardiopulmonary instability.
• Neonates: Patients aged 28 days or younger receiving the drug ceftriaxone.

Age and Condition Restrictions

• Pediatric Use: The product is not recommended for children under the age of two years because its fixed composition does not meet their specific nutritional requirements.
• Organ Impairment: Use requires caution and monitoring in adults with renal impairment, hepatic impairment, or hyperglycemia (diabetes) due to the risk of fluid, electrolyte, and metabolic imbalances.

Interactions with other medicines and products

The official regulatory profile for Kabiven Peripheral focuses on interactions related to its chemical composition and its pharmacodynamic effects, primarily concerning physical incompatibility and anticoagulant activity.

Contraindicated and Restricted Combinations

Simultaneous co-administration with Ceftriaxone via a Y-site connection is strictly contraindicated due to the risk of calcium-ceftriaxone precipitation, a potentially serious physical incompatibility. This restriction is absolute for all patients. Furthermore, this combination is an absolute contraindication in neonates (28 days of age or younger), even if separate infusion lines or sequential administration are used, as stated in regulatory labeling.

For patients older than 28 days, Ceftriaxone may be administered sequentially, provided the infusion line is thoroughly flushed with a compatible fluid between the administrations to comply with the mandated timing-separation rules.

Pharmacodynamic Interactions

The product's lipid emulsion component may lead to a pharmacodynamic interaction with coumarin derivatives, such as Warfarin. Official documents state that this interaction may counteract the anticoagulant effect, requiring monitoring of laboratory parameters that assess coagulation status.

No specific interactions mediated by Cytochrome P450 enzymes or drug transporters are documented in the official regulatory labeling. There are no explicitly documented interactions with food, alcohol, or herbal products.

Kabiven peripheral functions as a direct substrate provider to cellular metabolic machinery following intravenous infusion into the systemic circulation. The compound is a sterile admixture containing dextrose, crystalline amino acids, and a lipid emulsion derived from soybean oil, along with electrolytes. Dextrose is rapidly transported into cells via glucose transporters (GLUTs) on the plasma membrane, entering the glycolysis pathway for conversion to pyruvate, ultimately fueling the Krebs cycle and oxidative phosphorylation to generate adenosine triphosphate (ATP). The amino acids are selectively distributed to various tissues, serving as substrates for ribosomal protein synthesis and as precursors in catabolic pathways to replenish intermediates of the Krebs cycle (anaplerosis). The lipid emulsion, composed primarily of triglycerides and phospholipids, is hydrolyzed by lipoprotein lipase (LPL) at the endothelial surface of peripheral capillaries. The resultant free fatty acids are taken up by muscle, liver, and adipose cells, where they undergo beta-oxidation in the mitochondria, yielding acetyl-CoA to further contribute to ATP production. The electrolyte components maintain cellular membrane potential and regulate fluid balance, supporting necessary electrochemical gradients for transport and signaling processes.

How to Use Kabiven peripheral

This section outlines the general principles and procedural requirements for administering Kabiven peripheral, a parenteral nutrition solution. This information focuses strictly on administration parameters and usage patterns.

Administration Method and Dosing Regimens

Kabiven peripheral is administered as an intravenous infusion into either a peripheral or central vein. The dosage is calculated based on the patient's body weight and nutritional needs, with the maximum recommended adult daily dose not exceeding 40 mL/kg of body weight. The infusion is typically delivered once daily over a prolonged period, specifically 12 to 24 hours, and the rate must be carefully controlled to not exceed 3.7 mL/kg/hour. This time constraint is critical for the patient's metabolic tolerance of the components.

Preparation and Procedural Requirements

Prior to infusion, the product requires a mandatory activation step: the vertical seals within the three-chamber bag must be broken and the contents thoroughly mixed to form a single, homogeneous emulsion.

Severe pre-existing conditions, such as fluid, electrolyte, or acid-base disorders, must be corrected before starting the infusion. Furthermore, baseline serum triglyceride levels must be measured before administration begins. Administration necessitates the use of a 1.2 mu m in-line filter and a dedicated intravenous line. The infusion is explicitly not recommended for pediatric patients under 2 years of age due to the fixed, non-adjustable formulation.

Recent Clinical Evidence Summary

Kabiven peripheral (Perikabiven) is a complete parenteral nutrition (PN) formulation approved for use as a source of calories, protein, electrolytes, and essential fatty acids in adult patients requiring intravenous nutrition when oral or enteral feeding is insufficient or contraindicated.

Comparative Efficacy and Safety

Clinical research involving Kabiven peripheral has primarily focused on establishing its safety and efficacy profile in the context of total parenteral nutrition (TPN) compared to traditionally compounded nutrition regimens.

• Nutritional Status: Studies have evaluated the product's ability to maintain or improve nutritional status. Key outcome measures in these trials often include surrogate efficacy parameters such as the change in serum prealbumin levels from baseline, which is an indicator of nutritional response. Results generally aim to show that the pre-mixed formulation is non-inferior to control regimens in delivering necessary macronutrients and correcting negative nitrogen balance.
• Adverse Events: The safety profile monitored in clinical settings has documented adverse reactions typical of parenteral nutrition, including metabolic changes and issues at the infusion site. The primary complication associated with peripheral infusion is venous thrombophlebitis (inflammation of the vein), the incidence of which is a key safety measure in trials comparing peripheral and central line administration.

Specific Populations and Limitations

Available evidence and regulatory limitations generally restrict the use of Kabiven peripheral to adult patients. The fixed content of the formulation is not typically recommended for pediatric patients under the age of two, including preterm infants, as it does not align with the specialized nutritional needs of that age group. Research continues to characterize the metabolic effects, including lipid clearance and glucose control, in various adult patient populations requiring short-term and longer-term TPN.

Key Studies & References

1. KABIVEN and PERIKABIVEN (amino acids, electrolytes, dextrose and lipid injectable emulsion) Combined Prescribing Information

Common questions about Kabiven peripheral (FAQ)

Q: Does Kabiven peripheral contain an egg derivative, and is this of concern for people with allergies?

A: Yes, Kabiven peripheral contains an egg derivative, specifically purified egg phospholipids, which is an ingredient in the fat emulsion. According to official product information, this is an important consideration for patients with a known hypersensitivity or severe allergic reaction to egg or soy protein, as the product also contains soybean oil. The presence of these ingredients means official information indicates it should not be used if a patient has these specific allergies, as it is a contraindication.

Q: What is the official recommended method for infusing Kabiven peripheral?

A: Regulatory documents state that Kabiven peripheral must be administered only by intravenous infusion. It is administered via a peripheral or central vein. The bag should be used immediately after the overpouch is opened and any additions are made to ensure the stability and sterility of the product.

Q: What is the maximum duration for a single infusion of Kabiven peripheral?

A: Official product information specifies that a single bottle or bag of Kabiven peripheral should be administered over a period of 12 to 24 hours. This duration is specified to allow the contents, which include fats, amino acids, and glucose, to be delivered at a controlled rate.

Q: What are the storage guidelines for Kabiven peripheral before and after opening?

A: According to the official product information, Kabiven peripheral should be stored in the outer carton to protect it from light and kept at a temperature below 25°C (77°F). After the protective overpouch is removed and the contents are mixed, the infusion should be started immediately. After preparation, official guidelines state the mixture can be stored for up to 24 hours in a refrigerator before use.

Q: Can I use Kabiven peripheral if the contents look separated or unusual?

A: Regulatory documents clearly state that the visual appearance of the product must be checked before use. If the fat emulsion is noticeably separated (meaning the oil and water layers are distinct) or if the solution appears in any way abnormal, official guidelines specify that the product must not be used.

Q: Is Kabiven peripheral suitable for treating metabolic acidosis?

A: No, the product's regulatory information lists severe metabolic acidosis as a condition where it is contraindicated (should not be used). Metabolic acidosis is a condition involving a dangerous build-up of acid in the body, which is a key safety consideration for this nutritional product.

Q: Can Kabiven peripheral be used in infants younger than two years old?

A: Official product information states that Kabiven peripheral is not recommended for use in children under two years of age. Nutritional needs for children in this age group are often complex, and this product's formulation is not typically used for them.

Storage and Disposal of Kabiven Peripheral

Storage and disposal must strictly adhere to regulatory guidelines to maintain product integrity and safety.

Storage Conditions

Disposal Instructions

Kabiven Peripheral is for single use only. Any solution remaining after the infusion is complete must be discarded. Unused product and all waste materials (including the overpouch and oxygen absorber) must be disposed of according to local pharmaceutical waste regulatory requirements (SmPC).